Published June 4, 2015 | Version v1
Journal article

Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy

  • 1. Department of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080 (China)
  • 2. Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060 (China)

Description

To investigate prognostic significance of clinical and pathological stages in patients with locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy (neo-CRT) and total mesorectal excision. 210 patients with locally advanced rectal carcinoma (cT3-4 or cN+) treated with neo-CRT followed by total mesorectal excision. Treatment outcomes were compared according to clinical and pathological stage. Overall survival (OS), disease free survival (DFS) among patients with different clinical stage and pathological stage after neo-CRT. The median follow-up time was 47 months (range, 14–98 months). Clinical T stage was associated with 5 year OS (p = 0.042) and 5 year DFS (p = 0.014) while clinical N stage was not associated with 5 year OS (p = 0.440), 5 year DFS (p = 0.711). Pathological T stage was associate with 5 year OS (p = 0.001) and 5 year DFS (p = 0.046); and N stage was associated with 5 year OS (p = 0.001), 5 year DFS (p = 0.002). The pathological stage was further classified into three groups: ypT0–2N0 in 91 patients (43.3 %), ypT3–4N0 in 69 patients (32.9 %) and ypT0–4N+ in 50 patients (23.8 %). While pathological stage (ypT0–2 vs ypT3–4N0 vs ypT0–4N+) was associated with 5 year OS (87.9 %, 75.5 %, 56.7 %, p = 0.000), 5 year DFS (74.5 %, 77.4 %, 50.5 %, p = 0.003). Multivariate analysis showed that ypN stage was an independent prognostic factor for patients 5 year DFS. Pathological stage is strongly associated with treatment outcomes in patients with locally advanced rectal carcinoma treated with neo-CRT followed by total mesorectal excision, which may be used as guidance for further individualized treatment

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-015-0425-5; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490617

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
10
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47070016
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; COMBINED THERAPY; MULTIVARIATE ANALYSIS; PATIENTS; RADIOTHERAPY; RECTUM
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; GASTROINTESTINAL TRACT; INTESTINES; LARGE INTESTINE; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; STATISTICS; THERAPY

Optional Information

Copyright
Copyright (c) Wen et al. 2015
Notes
PMCID: PMC4490617; PMID: 26040453; PUBLISHER-ID: 425; OAI: oai:pubmedcentral.nih.gov:4490617